Lynavoy
What Lynavoy is used for
Lynavoy is indicated for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Lynavoy
- Active substance
- Linerixibat
- Disease area
- Liver Cirrhosis, Biliary; Pruritus
- Medicine group
- Bile and liver therapy
- ATC code
- A05AX
- Marketing authorisation holder
- GlaxoSmithKline Trading Services Limited
- Authorised in the EU since
- 2026
Official information
In the USA
Same active substance: Lynavoy
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lynavoy used for?
Lynavoy is indicated for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC).
What is the active substance in Lynavoy?
Lynavoy contains Linerixibat.
Who makes Lynavoy?
The EU marketing authorisation holder is GlaxoSmithKline Trading Services Limited.
Is Lynavoy an orphan medicine?
Yes. Lynavoy is designated an orphan medicine in the EU, for a rare disease (Liver Cirrhosis, Biliary; Pruritus).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU